Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection

Journal of Infectious Diseases

Volumn 198, Issue 8, 2008, Pages 1113-1122

  Landovitz, Raphael J ^a,f,g   Angel, Jonathan B ^b   Hoffmann, Christian ^c   Horst, Heinz ^c   Opravil, Milos ^e   Long, Jianmin ^a   Greaves, Wayne ^a   Fätkenheuer, Gerd ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VICRIVIROC; ZIDOVUDINE;

ADD ON THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPOSI SARCOMA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SINUSITIS; SKIN TOXICITY; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 54749134143     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592052     Document Type: Article

References (39)

1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
2. Little SJ, May S, Hecht F, et al. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia (abstract). Antivir Ther 2006; 11:S110.
3. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-80.
4. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-66.
5. Sabin CA, Work SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. D:A:D Study Group. Lancet 2008; 371:1417-26.
6. Stein JH, Currier JS. Risk of myocardial infarction and nucleoside analogues. Lancet 2008; 371:1391-2.
7. Calza L, Manfredi R, Chiodo F. Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. Metab Syndr Relat Disord 2004; 2:241-50.
8. Autar RS, Boyd MA, Wit FW, et al. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antivir Ther 2007; 12:1265-71.
9. Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004; 36:244-53.
10. Demarest J, Bonny T, Vavro C, et al. HIV co-receptor tropism in treatment naive and experienced subjects. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC (abstract H-1136). Herndon, VA: ASM Press, 2004.
11. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-74.
12. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-72.
13. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
14. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:668-9.
15. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
16. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine 1997; 3:252-3.
17. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998; 4:786-93.
18. + cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
19. Kozal MJ, Ramachandran RV, Shafer RW. Prevalence of HIV-1 syncytium-inducing phenotype. Ann Intern Med 1994; 120:811.
20. Koot M, van Leeuwen R, de Goede RE, et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999; 179:254-8.
21. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-74.
22. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-9.
23. Dunkle LM, Keung A, Sansone A, Strizki J. Vicriviroc is a novel, potent CCR5 inhibitor with outstanding pharmaceutic, pharmacokinetic and pharmacodynamic (PK/PD) properties (abstract). Retrovirology 2005; 2:S12.
24. Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-300.
25. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-75.
26. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual-mixed-tropic HIV-1: 24-weed results of a phase 2b exploratory trial (abstract THLB0215). In: Program and abstracts of the XVIth International AIDS Conference, Toronto, Canada, 2006.
27. Mosley M, Smith-Burchnell C, Mori J, et al. Resistance to the CCR5 antagonist maraviroc is characterized by dose response curves that display a reduction in maximal inhibition (Plateau) (abstract 598). In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, 2006.
28. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-71.
29. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212-28.
30. Holuigue S, Shan M, Ketas T, Moore J. Co-receptor switched and CCR5 inhibitor-resistant HIV-1 variants are generated in response to different selection pressures in vitro (abstract 164). In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
31. Ketas TJ, Kuhmann SE, Palmer A, et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007; 364:281-90.
32. Broder CC, Jones-Trower A. Coreceptor use by primate lentiviruses. In: Kuiken CL, Foley B, Hahn B, et al., eds. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, 1999:517-41.
33. Simmons G, Reeves JD, Hibbitts S, et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev 2000; 177:112-26.
34. Azevedo-Pereira JM, Santos-Costa Q, Mansinho K, Moniz-Pereira J. Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 2003; 313:136-46.
35. Yi Y, Singh A, Isaacs SN, Collman RG. A CCR5/CXCR4-independent coreceptor pathway on human macrophages supports efficient SIV env-mediated fusion but not infection: implications for alternative pathways of viral entry. Virology 2001; 284:142-51.
36. Gulick R, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007; 196:304-12.
37. Tsibris A, Paredes R, Su Z, et al. Vicriviroc therapy and EBV plasma viral loads in HIV-1-infected treatment-experienced subjects (abstract 844). In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
38. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-6.
39. Zingman B, Suleiman J, de Jesus E, et al. Vicriviroc in combination therapy with an optimized ART regimen for treatment-experienced subjects: VICTOR-E1 (abstract 795). In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008.